Navigation Links
Peregrine Researchers Present New Preclinical Data at AACR Annual Meeting Confirming Unique Anti-Tumor Mechanism of Bavituximab
Date:4/15/2008

ng and dosing patients and the two other trials are expected to begin shortly. Bavituximab is in clinical trials in the U.S. in patients with advanced solid tumors and in patients co-infected with HCV and HIV.

No. 4079: Monica L. Friedrich, Claudia I. Guevara, Daniel M. Falcon, Longen Zhou, Connie Chang and Bruce Freimark, Antibody targeting of phosphatidylserine produces a cytokine microenvironment that enhances innate anti-tumor immune responses, Peregrine Pharmaceuticals, Inc., April 15, 2008, 8:00 AM - 11:00 AM PDT

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that results from future preclinical studies and clinical trials will not correlate with the results of these preclinical studies. It is important to note that the company's ac
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
2. Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrines anti-PS Vascular Targeting Antibodies
3. Clinical Experience With Peregrines Anti-Cancer Agent Bavituximab Presented at Leading Symposium on Anti-Angiogenic Agents
4. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
5. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
6. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
7. Peregrine Announces Addition of The Johns Hopkins Hospital as Study Site for Bavituximab Trial in HCV Patients Co-Infected With HIV
8. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
9. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
10. Peregrine Pharmaceuticals Doses First Patient in Clinical Trial of Bavituximab in HCV Patients Co-Infected With HIV
11. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)..., SALT LAKE CITY, Nov. 27 /PRNewswire-FirstCall/...tems, Inc. (NYSE: VAR ), a premier supplier of X... will exhibit its full range of detectors at the R...29 - December 3, 2009. Varian will also be exhibi... as well as specialized cancer treatment technolog...
(Date:11/25/2009)..., CANOGA PARK, Calif., Nov. 25 Pr...ce rankings in the American Academy of Family Phys...09 EHR User Satisfaction Survey for improving medi...ement, all critical for new ARRA Stimulus legislat...g their EMR had a positive effect in determining t...
(Date:11/25/2009)..., PRINCETON, N.J., Nov. 25 /PRNewswire-FirstCall/ ...tage pharmaceutical company committed to discoveri...treat viral infections, reported financial results...September 30, 2009 Pharmasset held $58.4 million i...s. ,, Pipeline Update and 2009 Highlights ,...
Breaking Medicine Technology:Varian Medical Systems to Highlight the Latest Digital Detectors, X-ray Tubes and Cancer Treatment Technology at the Radiological Society of North America (RSNA) Annual Meeting in Chicago 2Praxis EMR Wins Top Rankings in 2009 AAFP EHR User Satisfaction Survey 2Pharmasset Reports Fiscal Year End 2009 Financial Results 2Pharmasset Reports Fiscal Year End 2009 Financial Results 3Pharmasset Reports Fiscal Year End 2009 Financial Results 4Pharmasset Reports Fiscal Year End 2009 Financial Results 5Pharmasset Reports Fiscal Year End 2009 Financial Results 6Pharmasset Reports Fiscal Year End 2009 Financial Results 7Pharmasset Reports Fiscal Year End 2009 Financial Results 8Pharmasset Reports Fiscal Year End 2009 Financial Results 9Pharmasset Reports Fiscal Year End 2009 Financial Results 10SNM urges Congress to support CARE bill 10161 1SNM urges Congress to support CARE bill 10161 2DIA Conference to Provide FDA EMEA Health Canada Emerging Regions NGO and Industry Perspectives on Global Vaccine Development 14277 1DIA Conference to Provide FDA EMEA Health Canada Emerging Regions NGO and Industry Perspectives on Global Vaccine Development 14277 2DIA Conference to Provide FDA EMEA Health Canada Emerging Regions NGO and Industry Perspectives on Global Vaccine Development 14277 3Study offers less complex minimally invasive procedure to treat heart valve leak 58466 1Study offers less complex minimally invasive procedure to treat heart valve leak 58466 2
...ty of Clinical Oncology meeting indicate CPX-1... data., PRINCETON, N.J., June 3 Celator Pharmace...hase 2 clinical trial in patients,with advanced co...of,irinotecan and floxuridine, based on the compan...lts were presented in a poster,presentation at the...
...y announced the FDA,510(k) submission of Yeast Tra...east species from positive blood cultures. Yeast T...,s easy-to-use, molecular-based PNA,FISH(TM) diagn... of,bloodstream pathogens in hours instead of days...ndida species is one of the most serious hospital,...
Other Medicine Technology:Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer 2Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer 3AdvanDx Submits Yeast Traffic Light PNA FISH(TM) for FDA 510(k) Clearance for Detection of Candida species in Positive Blood Cultures 2AdvanDx Submits Yeast Traffic Light PNA FISH(TM) for FDA 510(k) Clearance for Detection of Candida species in Positive Blood Cultures 3
(Date:11/27/2009)...RNewswire-FirstCall/ -- GSI Group Inc. (Pink Sheet...technology products and semiconductor systems, tod...,s shareholders has been scheduled for Friday, Apr... will be announced in due course. As previously a...e from Stephen Bershad, a holder of greater than t...
(Date:11/27/2009)...wswire-FirstCall/ -- The Gymboree Corporation (Nas..., will present at the NASDAQ OMX 23rd Investor Pro...London, England, on Wednesday, December 2, 2009, a...ast of The Gymboree Corporation,s presentation ove... click on "Our Company" at the bottom of the page,...
(Date:11/27/2009)...ings has announced that it has become a national s...gest nonprofit organizations dedicated to arthriti... Delray Beach, FL (Vocus) November..., a company specializing in the marketing and reta...as announced today that is has become a national s...
(Date:11/27/2009)...™ announced today that Spectrum Health (Gran...erprise orthopedic templating solution and its Tra... (PRWEB) November 27, 2009 -- Voyant Heal...and Rapids, Michigan) has licensed its TraumaCad E...raumaCad Extend workflow solution, to allow its or...
(Date:11/26/2009)...re/ -- With cold and flu season upon us, it,s more...ontrol the spread of infections and avoid illness....urselves healthy, but to avoid transmitting illnes... (certified in infection-control), nursing directo... Hospital for Special Surgery (HSS) in Manhattan. ...
Breaking Medicine News(10 mins):Health News:GSI Group Calls Shareholders Meeting 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 4Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 3Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 4
...of control, 'in'? A new report by the American Me...reports of college girls and their wild (s) ways!/...s revealed that breaking out of control and going ...k drinking meant bingeing on booze, getting them a...
...nder pressure as it is asked to improve its labor ...dham Clinton who has had deep// ties with the comp...erved on Wal-Mart's board of directors for six yea...Democratic activists, she has largely steered clea...
...nd relief at Norfolk as surgeons at the Norfolk an...green signal to make available the breast// cancer...-2 gene. "We made the business case and submi...he N&N. "About one in five women with breast cance...
...by the British Heart Foundation says that British ... a victim to heart disease than people// of Europe...iabetes as compared to 3 percent of the general po...outh East Asians in the UK, said lead author Profe...
...dy involving 38 populations across 21 countries, r...cross the globe are inexplicably dropping.// "...ations, but it went down in most of them," said Pr...r to have a cross- population effect. Most importa...
...esistant bacterial and fungal infections of the or...odynamic therapy (PDT)//, argue researchers from t...ne. Photodynamic therapy is commonly employe...hagus. The treatment modality involves admin...
Other Medicine News:Health News:Infections Of The Oral Cavity Can Be Treated By Photodynamic Therapy 2
ImmuLisa™ IgM-ACA anti-Cardiolipin Antibody (ACA) Kit
Leica L-70 Style Surgical Microscope Video Adapter from ImagingPlanet
Leica L-55 Style Surgical Microscope Video Adapter from ImagingPlanet
Leica® L-70 Style Surgical Microscope Adapter from ImagingPlanet
Medicine Products: